首页> 中文期刊>国际医药卫生导报 >醋酸亮丙瑞林微球联合孕三烯酮治疗子宫腺肌病的临床效果

醋酸亮丙瑞林微球联合孕三烯酮治疗子宫腺肌病的临床效果

摘要

目的 探究醋酸亮丙瑞林微球联合孕三烯酮治疗子宫腺肌病的效果.方法 选取2014年1月至2016年7月本院收治的子宫腺肌病患者84例,随机分为对照组和联合组,各42例.对照组给予醋酸亮丙瑞林治疗,联合组在对照组基础上联用孕三烯酮,观察比较两组治疗前、治疗结束时、治疗后2个月痛经VAS评分、月经量PBAC评分、子宫体积和血清生殖激素水平.结果 联合组痛经VAS评分、月经量PBAC评分和子宫体积改善明显优于对照组,差异具有统计学意义(均P<0.05);两组治疗结束时FSH、LH和E2水平均较治疗前降低,且联合组水平明显低于对照组(P<0.05);治疗后2个月,联合组和对照组FSH、LH和E2水平回升,两组FSH、LH水平差异无统计学意义(均P>0.05),联合组E2水平明显低于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05).结论 醋酸亮丙瑞林微球联合孕三烯酮治疗子宫腺肌病效果好且安全性良好,值得临床推广应用.%Objective To investigate the efficacy of leuprolide acetate combined with gestrinone in the treatment of uterine adenomyosis.Methods A total of 84 patients with uterine adenomyosis treated at our hospital from January,2014 to July,2016 were enrolled and randomly divided into a control group and a combination group,42 cases for each group.The control group were treated with leuprolide acetate and the combination group with leuprolide acetate and gestrinone.The VAS scores of dysmenorrhea,PBAC scores of menstrual amount,uterine volumes,and serum reproductive hormone levels of the two groups before treatment,at the end of the treatment,and 2 months after the treatment were observed and compared.Results The VAS score,the PBAC score,and the uterine volume of the combination group were significantly better than those of the control group (all P < 0.05).The levels of FSH,LH,and E2 were lower at the end of than before the treatment in both groups.The levels of FSH,LH,and E2 in the combination group were significantly lower than those in the control group at the end of the treatment (all P < 0.05).The levels of FSH,LH,and E2 2 months after treatment increased in both groups,while there were no statistical differences in the levels of FSH and LH between the two groups,but the level of E2 was significantly lower in the combination group than in the control group (P < 0.05).There was no statistical difference in the incidence of adverse reactions between the two groups (P > 0.05).Conclusion Leuprolide acetate combined with gestrinone in the treatment of uterine adenocarcinoma is effective and safe,so it is worth being clinically generalized.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号